RLYB Research and Charts

RLYB - Rallybio Corp (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2026-02-10)

Last 4.80	Change ⇑ +0.10 (+2.13%)	Volume 7,225
	Open 4.70	High 5.00	Low 4.70

8EMA (Daily) 2.81	40EMA (Daily) 1.24	50EMA (Daily) 1.13	STO (Daily) 56.972	MACD Hist (Daily) 0.587
8EMA (Weekly) 2.295	40EMA (Weekly) 1.05	50EMA (Weekly) 1.03	STO (Weekly) 61.173	MACD Hist (Weekly) 0.524


Company Profile
Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.